Core B: BSL3 Advanced Technologies and Animal Infection Core

项目概要/摘要（核心B，Stanley） 由结核分枝杆菌（Mycobacterium tuberculosis）感染引起的结核病（TB）仍然是人类疾病的主要原因。 发病率和死亡率，特别是在发展中国家。耐药的M. 结核病增加了开发新疫苗和治疗方法以结束这一全球流行病的紧迫性。 我们长期以来的P01项目的首要目标是确定先天免疫的原理， 认识到需要开发治疗和预防疾病的创新工具， 预防人类感染。这个P01项目代表了从解决基本机制到 通过应用我们团队的协作见解来解决具有独特挑战性的问题， 结核病疫苗的研发结核病研究本身就很困难，因为它需要专门的设施， 基础设施，具有严格的生物安全，培训和监督要求，以便安全地使用此 生物安全三级病原体。此外，P01的成功需要集成和协作鼠标- 基于感染和疫苗接种的研究，这将需要高度的标准化和监督， 培训、程序和核心试剂。该核心将通过提供以下服务来克服这些障碍： 为该计划的所有四个实验室提供全面的、最先进的研究支持， 并对M.以可靠、综合和具有成本效益的方式治疗结核病。

Project Summary/Abstract (Core B, Stanley) Tuberculosis (TB), caused by infection with Mycobacterium tuberculosis, remains a major cause of human morbidity and mortality, particularly in the developing world. The spread of antibiotic resistant strains of M. tuberculosis has increased the urgency to develop new vaccines and therapeutics to end this global pandemic. The over-arching goal of our long-standing P01 Project has been to identify the principles of innate immune recognition that are shared across diverse pathogens needed to develop innovative tools for treating and preventing infections in humans. This P01 project represents a shift from tackling basic mechanisms towards this goal by applying the collaborative insights of our group to tackle the uniquely challenging problem of vaccine development for TB. TB research is inherently difficult as it requires dedicated facilities and infrastructure, with stringent biosafety, training, and oversight requirements in order to work safely with this biosafety level 3 pathogen. Furthermore, success of the P01 requires integrated and collaborative mouse- based infection and vaccination studies which will require a high degree of standardization and oversight in training, procedures and core reagents. This Core will function to overcome these barriers by providing comprehensive, state-of-the-art research support to all four laboratories of this Program for the manipulation and study of M. tuberculosis in a reliable, integrated, and cost-efficient manner.